According to Sunovion Pharmaceuticals, data from a year-long clinical trial comparing the safety of Brovana arformoterol tartrate inhalation solution versus placebo in patients with moderate-to-severe COPD show no increased risk of exacerbations or death due to a respiratory event. Fewer than 10% of patients treated with 15 mcg of Brovana twice daily had serious respiratory events compared to approximately 15% of patients treated with placebo. In addition, mean time to the first event was longer for patients using Brovana who experienced an event.
Sunovion VP of Clinical Development and Medical Affairs Alistair Wheeler commented, “These results demonstrate no increased risk of COPD-related exacerbations leading to hospitalizations and respiratory death in patients taking Brovana versus those taking placebo, further supporting the long-term safety profile of Brovana. These data, along with our continued commitment to research and development in COPD, affirm Sunovion’s pledge to helping COPD patients achieve long-term symptom control by providing bronchodilator treatment via nebulized delivery.”
Read the Sunovion press release.
